Jeff Cerny
Analyst · Ladenburg
Thanks and good morning everyone. It was another strong quarter for our net investment income, which continued to exceed our distribution. As Bilal mentioned, we made significant progress ramping up our senior loan facility. We believe this entity is attractive for our shareholders by increasing our focus on lower yielding first lien senior secured loans to larger borrowers, which we believe will improve our ROE. In connection with this new financing facility, the company's investment advisor has agreed to waive a portion of its base management fee, it has agreed to reduce its base fee to 1% from 1.75% on assets held in the senior loan subsidiary when statutory leverage is above one times debt to equity. We deployed approximately $41.3 million in the third quarter, consisting of $13.4 million to existing portfolio companies and $27.9 million in five new companies. The new investments consistent mostly a floating rate senior secured loans to larger companies funded through our new financing facility and our SBIC. Turning to the financials, starting with the income statement, total investment income for the quarter was approximately $13.9 million approximately a $1 million increase over the second quarter. This increase was driven by a higher overall invested balance during the quarter partly offset it by declining LIBOR. Total expenses of $9 million increased $1 million compared to the prior quarter. This increase was driven by interest expense due to higher outstanding line of credit balances used to fund our investments and management fees due to more dollars invested during the quarter. Resulting net investment income per share of $0.36 remain stable again, this was above our $0.34 distribution. Net unrealized appreciation approximated only 0.6% of the overall cost of our investments. Turning to our balance sheet, we had approximately $8 million of un-invested cash at the end of the quarter, compared to $9 million last quarter. Of the $8 million of cash on our balance sheet, $4 million of that cash was in our SBIC. As Bilal mentioned, shortly after quarter end, we priced and closed a $50 million seven-year bond offering at 5.95%, which we use to paydown our PacWest line of credit. As of earlier this week, we have approximately $1.6 million of cash $100 million of undrawn commitment on our PacWest line of credit and $102.8 million of undrawn commitment on our new senior loan facility. Please note that cash and our loan facilities varies based on the asset mix and the amount of cash we deploy as equity. Our debt to equity ratio at the end of the quarter was about 1.2 times excluding our SBIC debt, and 2.1 times including the SBIC debt. As previously mentioned on this and prior calls, the SBIC does not count towards the leverage test. As also mentioned we would be comfortable increasing our leverage further in order to invest in senior secured loans of larger companies, which will primarily be done through our new senior loan subsidiary. Our net asset value was $12.74 per share compared to $12.95 in the prior quarter. The decline was largely due to net unrealized appreciation related to fair values determined at the end of the quarter. I would like to discuss in further detail the reason for the net unrealized depreciation fair value this quarter. A substantial portion of the unrealized depreciation related to Constellis a portfolio company that provides security, operational and risk management support to government and commercial clients. I want to note that the company is current on its payments and based on discussions with management they have stressed that they have adequate liquidity to fund operations. The company has a growing backlog and expects sequential performance improvement. The sponsor has substantial amount of cash invested in this business and we expect continued focus from the sponsor. As Bilal mentioned in this environment, we believe that certain loan prices have been disproportionately penalized even for slight underperformance which is reflected in lower loan bids and trades that negatively impact fair value. The broader lending environment has had softness and over the last year, loan prices have been soft relative to their peaks in October of 2018. We believe this is in large part related to supply demand imbalance resulting from 12 straight monthly outflows of cash from retail funds and invest in loans. More recently, we believe that this imbalance in a broader market has begun to shift the balance in favor of lenders who have more influence on loan structures. Turning back to our portfolio, as Bilal mentioned, we had no new nonaccrual this quarter at fair value we currently have only 0.1% of the portfolio on nonaccrual, at cost we currently have only 2.5% of the portfolio on nonaccrual. This is the fifth consecutive quarter with no new nonaccruals. Looking at the overall health of the portfolio, we saw the majority of our borrowers exhibit a quarter-over-quarter increase in revenue. We continue to watch our portfolio closely and we are not seeing any significant sector concerns in our portfolio. As far as our investments at the end of the quarter, we had investments in 73 companies totaling approximately $502 million on a fair value basis. As a percentage of cost, our investments were approximately 78% senior secured loans, 11% subordinated debt, 4% structured finance notes and 7% equity approximately two-thirds of which is in preferred equity securities. 90% of our loan investments were floating rate. Our portfolio remains diversified with an average investment in each portfolio company of approximately $6.8 million or 1.4% of the portfolio’s total fair value. The overall weighted average yield to cost on our performing debt investments was approximately 10.8% at September 30, compared to 11.4% at June 30. As expected, most of that decrease was driven by our focus on loans to larger companies, many of which are in the new senior loan subsidiary. Before I turn the call back to Bilal, we would like to highlight one of our investments from the quarter, New York Bariatric Group. We made a $10 million investment in a floating rate senior secure term loan, founded nearly 20 years ago, New York Bariatric Group is one of the largest providers of bariatric surgery and weight management solutions in the U.S. The five year facility has a full covenant package. The last dollar of debt leverage at closing was approximately 3.8 times and the pricing stands today at 7.1%. With that, I will turn the call back over to Bilal.